| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/20/2001 | CN1067254C Medicine for curing coronary heart disease and production technology |
| 06/20/2001 | CN1067243C Medicinal Preparation for curing angiocardiopath |
| 06/20/2001 | CN1067222C Health-care food for invigorating brain and anti tiredness |
| 06/19/2001 | US6248895 Benzofuroxan compound, method of preparation, pharmaceutical composition and method of treatment using the same |
| 06/19/2001 | US6248888 Heating 2-chloro-4-amino-6,7-dimethoxyquinazoline and 1-(2-tetrahydrofuroyl)piperazine in a polar organic reaction solution |
| 06/19/2001 | US6248882 Via dioxolane intermediates |
| 06/19/2001 | US6248864 Compounds and methods and modulating tissue permeability |
| 06/19/2001 | US6248791 Stimulating the differentiation of preadipocytic cells and therapies based thereon |
| 06/19/2001 | US6248787 Reducing cachexia |
| 06/19/2001 | US6248785 IL-8 receptor antagonists |
| 06/19/2001 | US6248783 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
| 06/19/2001 | US6248767 Formulation of sulfonamides for treatment of endothelin-mediated disorders |
| 06/19/2001 | US6248765 Imidazole derivatives as histamine receptor H3 (ANT) agonists |
| 06/19/2001 | US6248755 Antiinflammatory agents; antiallergens; autoimmune diseases |
| 06/19/2001 | US6248754 Psychological disorders |
| 06/19/2001 | US6248747 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 06/19/2001 | US6248729 Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
| 06/19/2001 | US6248717 Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | US6248358 Bioadhesive progressive hydration tablets and methods of making and using the same |
| 06/19/2001 | US6248341 Method of treating topical angiogenesis-related disorders |
| 06/19/2001 | US6248327 Using antibody |
| 06/19/2001 | US6248318 Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| 06/19/2001 | CA2218616C Nitrosylated neuropeptides |
| 06/19/2001 | CA2190973C Novel 4,6-diarylpyrimidine derivatives and salts thereof |
| 06/19/2001 | CA2172187C Method of incorporating drugs into a polymer component of stents |
| 06/19/2001 | CA2125964C Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists |
| 06/14/2001 | WO2001042794A2 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | WO2001042471A2 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042368A1 Substituted phthalocyanines and their precursors |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042281A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | WO2001042272A2 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | WO2001042265A2 N6 heterocyclic 8-modified adenosine derivatives |
| 06/14/2001 | WO2001042254A1 Benzamidine derivatives |
| 06/14/2001 | WO2001042247A1 Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same |
| 06/14/2001 | WO2001042244A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 06/14/2001 | WO2001042241A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | WO2001042238A1 Heterocyclic derivatives |
| 06/14/2001 | WO2001042231A2 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042204A1 N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof |
| 06/14/2001 | WO2001042199A1 Amidinophenylpyruvic acid derivative |
| 06/14/2001 | WO2001042191A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/14/2001 | WO2001042189A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 06/14/2001 | WO2001041807A2 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 06/14/2001 | WO2001041803A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-α AND CD95L IN A MEDICAMENT |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041791A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | WO2001041775A2 Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response |
| 06/14/2001 | WO2001041764A1 Use of isoquinoline and quinoline containing substances as imidazoline receptor ligands |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041756A2 Method and composition for treatment of ischemic neuronal reperfusion injury |
| 06/14/2001 | WO2001041754A2 Inhibitors of collagen-induced platelet aggregation |
| 06/14/2001 | WO2001041744A1 Chronotherapeutic diltiazem formulations and the administration thereof |
| 06/14/2001 | WO2001041743A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | WO2001041704A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | WO2001041703A2 Method for treating allergic diseases |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001041535A2 Eplerenone crystalline form |
| 06/14/2001 | WO2001027101A3 Anhydrous salt |
| 06/14/2001 | WO2001018040A3 Use of leptin in inhibition of endothelial cell proliferation |
| 06/14/2001 | WO2001007022A3 Azetidine compounds in cns and eye diseases |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001002373A8 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | WO2000032631A3 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof |
| 06/14/2001 | US20010003749 Arylpiperazines having activity at the serotonin 1A receptor |
| 06/14/2001 | US20010003747 Useful in treating or in preventing melatoninergic disorders |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2396739A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | CA2395039A1 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394891A1 Substituted phthalocyanines and their precursors |
| 06/14/2001 | CA2394060A1 Transmucosal administration of phosphodiesterase inhibitor for the treatment of erectile dysfunction |
| 06/14/2001 | CA2393779A1 Combination of compounds that inhibit the biological effects of tnf-.alpha. and cd95l in a medicament |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393510A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | CA2393463A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2392568A1 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | CA2390857A1 Inhibitors of collagen-induced platelet aggregation |
| 06/14/2001 | CA2362845A1 Eplerenone crystalline form |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2362669A1 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | CA2361647A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/13/2001 | EP1107005A1 Method for identifying inhibitors of cytokinesis |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106608A1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them |